Developments include $7.8 million cash position, go public transaction and financing, FDA clinical trial progress, licensing expansion, and first patent issuance Vancouver, British Columbia, August 16, 2021 – Filament Health Corp. (NEO:FH) (“Filament” or the “Company”), a leading exclusively-natural psychedelic drug development company, today released its second quarter unaudited financial results…


Previous articleKeeping Participants Safe in Psychedelic Research
Next articleMydecine Reports Second Quarter 2021 Financial Results and Provides Business Update